Under section ''Guidelines for systemic treatment'' it should read (a) ER-positive patients: premenopausal and postmenopausal patients receive low-dose tamoxifen (20 mg/week) or participate in the IBIS-2 trial, which has two arms: after quadrantectomy, Tamoxifen (20 mg/day) versus Anastrazole (1 mg/day); after mastectomy, Anastrazole (1 mg/day) versus placebo.
Instead of (a) ER-positive patients: premenopausal and postmenopausal patients receive low-dose tamoxifen (20 mg/week) or participate in the IBIS-2 trial, which has two arms: after quadrantectomy, Tamoxifen (20 mg/day) versus Anastrazole (100 mg/day); after mastectomy, Anastrazole (100 mg/day) versus placebo.
The online version of the original article can be found under doi:10.1007/s10549-010-1124-4.
